Treatment of Heart Failure with Mildly Reduced Ejection Fraction

Heart failure with mildly reduced ejection fraction (HFmrEF) affects patients with a left ventricular ejection fraction of 41–49%. This protocol addresses first-line pharmacological management for patients with current or previous symptomatic HFmrEF.

Clinical Focus Patients with current or previous symptomatic HFmrEF — particularly those with LVEF toward the lower end of the mildly reduced spectrum — in whom guideline-directed pharmacotherapy is indicated to reduce cardiovascular risk.

Treatment Approach

Current evidence supports adding an evidence-based beta blocker for HFrEF as a core component of management. A structured combination of additional agent classes is also included in the full protocol — agent selection criteria, sequencing, and further detail are not shown here.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1161/CIR.0000000000001063

Among patients with current or previous symptomatic HFmrEF (LVEF, 41%–49%), use of evidence-based beta blockers for HFrEF, ARNi, ACEi, or ARB, and MRAs may be considered to reduce the risk of HF hospitalization and cardiovascular mortality, particularly among patients with LVEF on the lower end of this spectrum.

View source ↗